Brokerage Radar: MOSL initiates coverage on Mankind Pharma





Company working on multiple levers to boost growth over the next three to five years

Company increasing the scope of business in chronic therapies

Company enhancing its presence in met metro/Tier-I cities

Expect a 16% earnings CAGR for MANKIND over FY24-27

Value MANKIND at 40x12M forward earnings to arrive at a TP of INR 2,650

Initiate coverage with a BUY rating (Source: ETNOW)


Comments